Amicus Therapeutics, Inc. (NASDAQ:FOLD) announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10), Bloomberg Earnings reports. Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The business had revenue of $10.90 million for the quarter, compared to the consensus estimate of $9.02 million. During the same period in the prior year, the company earned ($0.33) EPS. Amicus Therapeutics’s quarterly revenue was up 419.0% on a year-over-year basis.
Amicus Therapeutics (NASDAQ:FOLD) traded up $0.17 during mid-day trading on Friday, reaching $13.22. 888,600 shares of the company traded hands, compared to its average volume of 3,227,132. Amicus Therapeutics has a fifty-two week low of $4.41 and a fifty-two week high of $16.60. The company has a quick ratio of 6.22, a current ratio of 6.32 and a debt-to-equity ratio of 0.39.
In related news, Director Michael Raab sold 10,000 shares of the stock in a transaction that occurred on Thursday, October 12th. The shares were sold at an average price of $14.25, for a total transaction of $142,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John F. Crowley sold 71,735 shares of the stock in a transaction that occurred on Wednesday, October 18th. The shares were sold at an average price of $14.75, for a total transaction of $1,058,091.25. Following the sale, the chief executive officer now directly owns 380,723 shares of the company’s stock, valued at $5,615,664.25. The disclosure for this sale can be found here. Over the last three months, insiders have sold 628,224 shares of company stock valued at $9,024,003. Company insiders own 3.40% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Amicus Therapeutics, Inc. (FOLD) Posts Earnings Results, Misses Expectations By $0.10 EPS” was originally posted by BBNS and is owned by of BBNS. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://baseballnewssource.com/markets/amicus-therapeutics-inc-fold-releases-earnings-results-misses-expectations-by-0-10-eps/1760005.html.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with our FREE daily email newsletter.